Spots Global Cancer Trial Database for entinostat
Every month we try and update this database with for entinostat cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery | NCT01207726 | Stage IA Non-Sm... Stage IB Non-Sm... | Azacitidine Entinostat Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | NCT02453620 | Anatomic Stage ... Anatomic Stage ... Breast Adenocar... Invasive Breast... Malignant Solid... | Biopsy Blood Sample Bone Scan Computed Tomogr... Entinostat Ipilimumab Nivolumab Pharmacogenomic... Pharmacological... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer | NCT01105377 | Recurrent Colon... Recurrent Recta... Stage IV Colon ... Stage IV Rectal... | entinostat azacitidine laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | NCT03280563 | Breast Neoplasm... | Atezolizumab (M... Bevacizumab Entinostat Exemestane Fulvestrant Ipatasertib Tamoxifen Abemaciclib | 18 Years - | Hoffmann-La Roche | |
| A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | NCT03250273 | Metastatic Chol... Cholangiocarcin... Pancreatic Canc... Metastatic Panc... Unresectable Pa... Unresectable Ch... | Entinostat Nivolumab Entinostat Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia | NCT01132573 | Acute Leukemias... Philadelphia Ch... Recurrent Adult... Untreated Adult... | entinostat clofarabine pharmacological... laboratory biom... | 21 Years - | National Cancer Institute (NCI) | |
| Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | NCT02453620 | Anatomic Stage ... Anatomic Stage ... Breast Adenocar... Invasive Breast... Malignant Solid... | Biopsy Blood Sample Bone Scan Computed Tomogr... Entinostat Ipilimumab Nivolumab Pharmacogenomic... Pharmacological... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia | NCT01159301 | Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Recurrent Adult... Unspecified Adu... | entinostat sorafenib tosyl... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. | NCT01928576 | Non-Small Cell ... Epigenetic Ther... | Azacitidine Entinostat Nivolumab CC-486 300 | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | NCT03924245 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... High Grade Fall... High Grade Ovar... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Primary Periton... Recurrent Endom... Recurrent Ovari... Recurrent Prima... | Entinostat Olaparib | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas | NCT03179930 | Lymphoma Relapsed Refractory | Entinostat Pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | NCT04708470 | Oropharyngeal C... Neck Cancer Human Papilloma... HPV Anal Cancer Cervical Cancer Penile Cancer Vulvar Cancer Vaginal Cancer Colon Cancer | Bintrafusp Alfa NHS-IL12 Entinostat | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas | NCT05053971 | Advanced Lympho... Advanced Malign... Advanced Pancre... B-Cell Non-Hodg... Metastatic Panc... Refractory B-Ce... Refractory Lymp... Refractory Mali... Refractory Panc... Refractory T-Ce... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | BET Bromodomain... Core Biopsy Entinostat | 18 Years - | National Cancer Institute (NCI) | |
| Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer | NCT01038778 | Clear Cell Rena... Metastatic Kidn... Stage III Renal... Stage IV Renal ... | Aldesleukin Computed Tomogr... Entinostat Fludeoxyglucose... Laboratory Biom... Pharmacological... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | NCT02780804 | Brain Stem Neop... Pineal Region N... Recurrent Lymph... Recurrent Malig... Recurrent Prima... Recurrent Visua... Refractory Lymp... Refractory Mali... Refractory Prim... Refractory Visu... | Entinostat Laboratory Biom... Pharmacological... | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | NCT03925428 | Advanced Lympho... Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Refractory B-Ce... Refractory Lymp... Refractory Mali... Refractory Panc... Refractory T-Ce... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Entinostat Molibresib | 12 Years - | National Cancer Institute (NCI) | |
| Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer | NCT03018249 | FIGO Grade 1 En... FIGO Grade 2 En... FIGO Grade 3 En... | Entinostat Hysterectomy Laboratory Biom... Medroxyprogeste... | 18 Years - | National Cancer Institute (NCI) | |
| An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma | NCT03765229 | Melanoma | Entinostat Pembrolizumab | 18 Years - 99 Years | UNC Lineberger Comprehensive Cancer Center | |
| Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye | NCT02697630 | Metastatic Uvea... | Pembrolizumab Entinostat | 18 Years - | Vastra Gotaland Region | |
| Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer | NCT02115594 | Breast Cancer | Fulvestrant Entinostat Placebo | - | Syndax Pharmaceuticals | |
| A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | NCT04708470 | Oropharyngeal C... Neck Cancer Human Papilloma... HPV Anal Cancer Cervical Cancer Penile Cancer Vulvar Cancer Vaginal Cancer Colon Cancer | Bintrafusp Alfa NHS-IL12 Entinostat | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer | NCT02115594 | Breast Cancer | Fulvestrant Entinostat Placebo | - | Syndax Pharmaceuticals | |
| Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | NCT03552380 | Renal Cell Carc... | Entinostat Nivolumab Ipilimumab | 18 Years - | Hoosier Cancer Research Network | |
| Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | NCT02708680 | Breast Cancer | Entinostat Atezolizumab Placebo | 18 Years - | Syndax Pharmaceuticals | |
| Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer | NCT03018249 | FIGO Grade 1 En... FIGO Grade 2 En... FIGO Grade 3 En... | Entinostat Hysterectomy Laboratory Biom... Medroxyprogeste... | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | NCT00313586 | Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Alkylating Agen... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult... | Azacitidine Entinostat Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma | NCT03765229 | Melanoma | Entinostat Pembrolizumab | 18 Years - 99 Years | UNC Lineberger Comprehensive Cancer Center | |
| Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | NCT02909452 | Neoplasms Neoplasms, Glan... Neoplasms by Hi... Bronchial Neopl... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Digestive Syste... Endocrine Gland... Carcinoma, Non-... Lung Diseases Breast Diseases Renal Neoplasm Solid Tumors | Entinostat Pembrolizumab | 18 Years - | Syndax Pharmaceuticals | |
| Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing | NCT00828854 | ER+ Breast Canc... | Entinostat Aromatase Inhib... | - | Syndax Pharmaceuticals | |
| BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) | NCT04296942 | Breast Cancer Triple Negative... HER2+ Breast Ca... Hormone Recepto... Metastatic Brea... | Brachyury-TRICO... Entinostat M7824 Ado-trastuzumab... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | NCT04631029 | Extensive Stage... Malignant Solid... Metastatic Mali... | Atezolizumab Carboplatin Entinostat Etoposide | 18 Years - | National Cancer Institute (NCI) | |
| Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | NCT01383447 | Philadelphia Ch... Recurrent Adult... | entinostat imatinib mesyla... laboratory biom... pharmacological... western blottin... immunohistochem... flow cytometry polymerase chai... high performanc... mass spectromet... | 18 Years - | National Cancer Institute (NCI) | |
| Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing | NCT00828854 | ER+ Breast Canc... | Entinostat Aromatase Inhib... | - | Syndax Pharmaceuticals | |
| Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | NCT03829930 | Prostate Adenoc... | Entinostat Enzalutamide | 18 Years - | George Washington University | |
| A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy | NCT03473639 | Metastatic Brea... Breast Cancer | Entinostat Capecitabine | 18 Years - | University of Virginia | |
| Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | NCT04631029 | Extensive Stage... Malignant Solid... Metastatic Mali... | Atezolizumab Carboplatin Entinostat Etoposide | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer | NCT01935947 | Recurrent Non-S... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-Sm... | Azacitidine Azacitidine Docetaxel Entinostat Gemcitabine Hyd... Irinotecan Hydr... Laboratory Biom... Pemetrexed Diso... | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer | NCT01349959 | Male Breast Car... Recurrent Breas... Stage IIIC Brea... Stage IV Breast... Triple-Negative... | Azacitidine Entinostat Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy | NCT03473639 | Metastatic Brea... Breast Cancer | Entinostat Capecitabine | 18 Years - | University of Virginia | |
| Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer | NCT02820961 | Breast Cancer Estrogen Recept... | entinostat exemestane | 18 Years - 85 Years | Syndax Pharmaceuticals | |
| Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | NCT02780804 | Brain Stem Neop... Pineal Region N... Recurrent Lymph... Recurrent Malig... Recurrent Prima... Recurrent Visua... Refractory Lymp... Refractory Mali... Refractory Prim... Refractory Visu... | Entinostat Laboratory Biom... Pharmacological... | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma | NCT03024437 | Metastatic Canc... Renal Cancer | Atezolizumab Bevacizumab Entinostat | 18 Years - | Indiana University | |
| Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC | NCT00602030 | Non-Small-Cell ... Carcinoma, Non-... | Entinostat Placebo Erlotinib | 18 Years - | Syndax Pharmaceuticals | |
| Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer | NCT05898828 | Neoplasms Esophageal Neop... Esophagus Neopl... Esophagus Cance... Neoplasms, Esop... Esophageal Canc... | Nivolumab Entinostat Montanide(R) IS... H1299 Cell Lysa... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | NCT00313586 | Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Alkylating Agen... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult... | Azacitidine Entinostat Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib | NCT00750698 | Non Small Cell ... | Entinostat Erlotinib | 18 Years - | Syndax Pharmaceuticals | |
| Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | NCT02897778 | Neoplasms Neoplasms, Glan... Neoplasms by Hi... Bronchial Neopl... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Digestive Syste... Endocrine Gland... Carcinoma, Non-... Lung Diseases Breast Neoplasm... Breast Diseases Renal Neoplasm Solid Tumors | Entinostat Placebo | 18 Years - | Syndax Pharmaceuticals | |
| Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma | NCT03024437 | Metastatic Canc... Renal Cancer | Atezolizumab Bevacizumab Entinostat | 18 Years - | Indiana University | |
| Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer | NCT03538171 | Advanced Breast... | Entinostat Placebo Exemestane | 18 Years - 75 Years | Taizhou EOC Pharma Co., Ltd. | |
| Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC | NCT03361800 | Breast Cancer Invasive Breast... ER-Negative PR-... | Entinostat | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) | NCT04296942 | Breast Cancer Triple Negative... HER2+ Breast Ca... Hormone Recepto... Metastatic Brea... | Brachyury-TRICO... Entinostat M7824 Ado-trastuzumab... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer | NCT02833155 | Breast Cancer | Entinostat Exemestane | 18 Years - 65 Years | Taizhou EOC Pharma Co., Ltd. | |
| Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery | NCT01886573 | Stage IA Non-Sm... Stage IB Non-Sm... Stage IIA Non-S... Stage IIB Non-S... Stage IIIA Non-... | Azacitidine Entinostat Laboratory Biom... Pharmacological... Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | NCT02708680 | Breast Cancer | Entinostat Atezolizumab Placebo | 18 Years - | Syndax Pharmaceuticals | |
| Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | NCT03552380 | Renal Cell Carc... | Entinostat Nivolumab Ipilimumab | 18 Years - | Hoosier Cancer Research Network | |
| Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer | NCT02833155 | Breast Cancer | Entinostat Exemestane | 18 Years - 65 Years | Taizhou EOC Pharma Co., Ltd. | |
| Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer | NCT05898828 | Neoplasms Esophageal Neop... Esophagus Neopl... Esophagus Cance... Neoplasms, Esop... Esophageal Canc... | Nivolumab Entinostat Montanide(R) IS... H1299 Cell Lysa... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | NCT00101179 | Acute Myeloid L... Chronic Myelomo... de Novo Myelody... Leukemia Myelodysplastic... Recurrent Adult... Secondary Acute... Secondary Myelo... | Azacitidine Entinostat | 18 Years - | National Cancer Institute (NCI) | |
| Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | NCT03552380 | Renal Cell Carc... | Entinostat Nivolumab Ipilimumab | 18 Years - | Hoosier Cancer Research Network | |
| Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | NCT02780804 | Brain Stem Neop... Pineal Region N... Recurrent Lymph... Recurrent Malig... Recurrent Prima... Recurrent Visua... Refractory Lymp... Refractory Mali... Refractory Prim... Refractory Visu... | Entinostat Laboratory Biom... Pharmacological... | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer | NCT01594398 | Lung Cancer Non Small Cell ... Breast Cancer Estrogen Recept... | entinostat entinostat Erlotinib Erlotinib Exemestane Exemestane | 18 Years - 90 Years | Syndax Pharmaceuticals | |
| Entinostat Neuroendocrine (NE) Tumor | NCT03211988 | Neuroendocrine ... | Entinostat | 18 Years - 99 Years | Columbia University | |
| Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer | NCT02437136 | Non-Small Cell ... Melanoma Mismatch Repair... | entinostat pembrolizumab | 18 Years - | Syndax Pharmaceuticals | |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | NCT03280563 | Breast Neoplasm... | Atezolizumab (M... Bevacizumab Entinostat Exemestane Fulvestrant Ipatasertib Tamoxifen Abemaciclib | 18 Years - | Hoffmann-La Roche | |
| Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia | NCT01159301 | Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Recurrent Adult... Unspecified Adu... | entinostat sorafenib tosyl... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents | NCT02936752 | Myelodysplastic... | Entinostat Pembrolizumab | 18 Years - | National Cancer Institute (NCI) | |
| Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer | NCT02437136 | Non-Small Cell ... Melanoma Mismatch Repair... | entinostat pembrolizumab | 18 Years - | Syndax Pharmaceuticals | |
| Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | NCT03925428 | Advanced Lympho... Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Refractory B-Ce... Refractory Lymp... Refractory Mali... Refractory Panc... Refractory T-Ce... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Entinostat Molibresib | 12 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
